Ovarian Cancer Clinical Trials in Omaha, Nebraska

11 studies are recruiting for ovarian cancer in Omaha, Nebraska right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

2. A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

   Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is us…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Nebraska Methodist Hospital ( Site 0004), Omaha, Nebraska

   Locations

   163 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07318558 on ClinicalTrials.gov

3. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

   The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Locations

   9 in total

   Run by

   Accent Therapeutics

   See if you can join NCT06799065 on ClinicalTrials.gov

4. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of Nebraska Medical Center Buffet Cancer Center, Omaha, Nebraska

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

5. A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

   This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

   Stage

   Phase 2

   Ages

   18 to 99

   Site

   Nebraska Methodist Hospital, Omaha, Nebraska

   Locations

   74 in total

   Run by

   Incyte Corporation

   See if you can join NCT07023627 on ClinicalTrials.gov

6. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

   The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Nebraska Methodist Hospital ( Site 0053), Omaha, Nebraska

   Locations

   196 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06824467 on ClinicalTrials.gov

7. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   11 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov

8. Integrated Cancer Repository for Cancer Research

   The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct char…

   Stage

   Not phased

   Ages

   19 to 110

   Site

   Methodist Estabrook Cancer Center, Omaha, Nebraska

   Locations

   42 in total

   Run by

   University of Nebraska

   See if you can join NCT02012699 on ClinicalTrials.gov

9. 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

   A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   4 in total

   Run by

   Radiopharm Theranostics, Ltd

   See if you can join NCT07189871 on ClinicalTrials.gov

10. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Omaha, Nebraska

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

11. Comprehensive Outcomes for After Cancer Health

    This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Nebraska Medical Center, Omaha, Nebraska

    Locations

    7 in total

    Run by

    Pack Health

    See if you can join NCT05349227 on ClinicalTrials.gov